This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Melatonin for the treatment of irritable bowel syndrome
Kewin Tien Ho Siah, Reuben Kong Min Wong, Khek Yu Ho
Kewin Tien Ho Siah, Reuben Kong Min Wong, Khek Yu Ho, Division of Gastroenterology and Hepatology, University Medicine Cluster, National University Hospital, Singapore 119228, Singapore
Kewin Tien Ho Siah, Reuben Kong Min Wong, Khek Yu Ho, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore
ORCID number: $[AuthorORCIDs]
Author contributions: Siah KTH, Wong RKM and Ho KY contributed equally to this work.
Correspondence to: Khek Yu Ho, Professor of Medicine, Chief, University Medicine Cluster, National University of Singapore Tower Block, Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore. firstname.lastname@example.org
Telephone: +65-67795555 Fax: +65-67794112
Received: October 28, 2013 Revised: December 17, 2013 Accepted: January 20, 2014 Published online: March 14, 2014
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain or discomfort, in combination with disturbed bowel habits in the absence of identifiable organic cause. Melatonin (N-acetyl-5-methoxytryptamine) is a hormone produced by the pineal gland and also large number by enterochromaffin cells of the digestive mucosa. Melatonin plays an important part in gastrointestinal physiology which includes regulation of gastrointestinal motility, local anti-inflammatory reaction as well as moderation of visceral sensation. Melatonin is commonly given orally. It is categorized by the United States Food and Drug Administration as a dietary supplement. Melatonin treatment has an extremely wide margin of safety though it may cause minor adverse effects, such as headache, rash and nightmares. Melatonin was touted as a potential effective candidate for IBS treatment. Putative role of melatonin in IBS treatment include analgesic effects, regulator of gastrointestinal motility and sensation to sleep promoter. Placebo-controlled studies in melatonin suffered from heterogeneity in methodology. Most studies utilized 3 mg at bedtime as the standard dose of trial. However, all studies had consistently showed improvement in abdominal pain, some showed improvement in quality of life of IBS patients. Melatonin is a relatively safe drug that possesses potential in treating IBS. Future studies should focus on melatonin effect on gut mobility as well as its central nervous system effect to elucidate its role in IBS patients.
Core tip: Irritable bowel syndrome (IBS) is a common disorder associated with significant disability and high social cost. This is partly due to lack of effective treatment with low side effects. Melatonin is a drug that was postulated to be a potential useful arsenal in battling IBS. Its role in analgesia has been recognized in several other fields of medicine. Several well-designed placebo-controlled trials in IBS patients had consistently showed improvement of abdominal pain when taking 3 mg of melatonin with no serious side effect. Future studies should examine the long term effect of Melatonin as well as its effect on central nervous system and gut motility.
Citation: Siah KTH, Wong RKM, Ho KY. Melatonin for the treatment of irritable bowel syndrome. World J Gastroenterol 2014; 20(10): 2492-2498
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain or discomfort, in combination with disturbed bowel habits in the absence of identifiable organic cause. It is associated with significant disability and health care costs. In the West, the prevalence of IBS in the community is reported to be between 10%-20%[1-3]. In Asia, we have also seen a steady rise of IBS in the community. In Singapore, prevalence of IBS was reported to be 2.3% in 1998, by the Manning criteria, and 8.6% in 2004 (as defined by the Rome II criteria). In addition, a recent study has shown that the disease burden extends beyond the patient and has significant impact on the spouse or family members as well, with burden proportionally increasing with IBS severity, underscoring the need for effective treatment of the patient’s symptoms.
Traditionally, IBS is treated with a combination of treatment modality, from antispasmodic, psychopharmacological treatment like tricyclic antidepressant to mindfulness therapy like hypnotherapy. Newer drugs such as linaclotide, prucalopride, tegaserod and lubiprostone have given hope to clinicians treating the many disabling symptoms of IBS. However, worry about potential side effects, the need for long-term medication and high drug costs have been a deterrent for many IBS patients. Melatonin is one of the drug that was identified as potentially useful in IBS especially for pain symptom as well as bowel motility in constipation predominant IBS.
Melatonin (N-acetyl-5-methoxytryptamine), a hormone produced by the pineal gland, has been studied as a potential treatment of circadian rhythm sleep disorders, cancer, immune disorders, cardiovascular diseases and insomnia[8,9]. The melatonin signal chemically regulates the sleep-wake cycle by causing drowsiness and lowering body temperature. The gastrointestinal tract is another large source of endogenous melatonin.
MELATONIN IN GASTROINTESTINAL TRACT
Melatonin is produced by enterochromaffin cells of the digestive mucosa. There is higher concentration of melatonin in the gastrointestinal tract than the blood or the pineal gland. The finding that the concentration of melatonin in the gastrointestinal tissues surpasses that in the blood by 10-100 times suggests that melatonin may play an important role in the digestive system. Circadian variation of gastrointestinal (GI) melatonin does not appear to be controlled by photoperiodicity (like the pineal gland), but by eating and food composition. A sharp increase in the content of melatonin in GI tract tissue and circulation in response to food intake was reported in volunteers[12,13]. Melatonin played several pivotal local intestinal functions: (1) Regulation of GI motility: Melatonin exerts both excitatory and inhibitory effects on gut smooth muscles. The precise mechanism through which melatonin regulates gastrointestinal motility is still not very clear. Small doses of melatonin accelerated the intestinal transit in rats, while high doses reversed this effect. In one study focusing on gastric emptying, melatonin partially inhibited gastric motility by activating sympathetic neurons. In the stomach, melatonin also reduces nitrergic myenteric innervation; (2) Anti-Inflammatory Reaction: It increases natural killer cell activity and Th2 cell mediated immune responses. Melatonin was shown to reduce the severity of intestinal inflammatory pathologies such as colitis in animal models. Melatonin had also been shown to scavenge reactive oxygen species and inhibit macrophage by suppressing proinflammatory gents including inducible nitric oxide synthase and cyclooxygenase-2[18-20]; and (3) Moderation of Visceral Sensation: Melatonin may also be involved in mediating gut visceral sensation because patients with functional abdominal pain are reported to have a lower urinary excretion of 6-sulphatoxy melatonin and to exhibit a circadian rhythm of lower amplitude compared with healthy controls.
Melatonin might be a candidate for IBS treatment based on the following considerations: (1) melatonin has analgesic effects which may help to alleviate abdominal pain and influence the sensation of abdominal distention in IBS patients; (2) melatonin has regulatory effects on gastrointestinal tract motility and sensation which may improve the bowel habits and alleviate abdominal pain or distention in IBS patients; (3) melatonin could have a sleep promoting effect which may useful to treat the sleep disturbance of IBS patients; and (4) melatonin has mood regulation and anti-stress effects which could help alleviate the abnormal psychological parameters observed in IBS patients. Thus, we believe that melatonin might serve the several aspects of IBS treatment strategy because it targets not only the psychological component, i.e., stress, anxiety, depression and sleep disorder but also the peripheral elements of abnormal bowel sensation and motility. Below we examine the possible mechanisms of melatonin in the treatment of IBS.
PHARMACOLOGY OF MELATONIN
Melatonin is commonly given orally though it also can be given via intravenous, intranasal or transbuccal routes. Melatonin is readily absorbed when it is administered via any route. It crosses all morphophysiological barriers, e.g., blood-brain barrier and placenta, with ease.
The absorption and bioavailability of melatonin varies widely. When given by mouth, peak melatonin concentration occurs within an hour and serum half-life is approximately 35-50 min. Because of its fast clearance, regular melatonin formulations can produce physiological levels for only 2-4 h. The typical dose range in studies of melatonin’s effects on sleep disturbance has been between 0.3-5 mg, with 2-3 mg commonly being used. Ingested melatonin that did not undergo first-pass metabolism in the liver is eventually metabolized, mainly in the liver. After conjugation with sulfuric or glucuronic acid, it is excreted by the kidneys. A single night-time dose is cleared by the following morning. Legal availability of melatonin varies in different countries from over the counter in United States to prescription only in other countries. It is categorized by the United States Food and Drug Administration as a dietary supplement. Melatonin treatment has an extremely wide margin of safety though it may cause minor adverse effects, such as headache, rash and nightmares. Studies of human subjects given varying doses of melatonin (1-6.6 g/d) for 30-45 d did not reveal abnormalities at the end of the test period except drowsiness[24,25]. However, in a placebo-controlled trial using 3-6 mg of melatonin for eight weeks on IBS women, drowsiness only happened in a minority of participants and there was no difference between the groups[26,27]. Lu et al also showed that baseline saliva melatonin levels were lower in IBS compare to normal control and oral melatonin supplement was able to increase the level of melatonin in the saliva.
WHAT ARE THE PUTATIVE SITES OF ACTION OF MELATONIN IN IBS?
Besides the bowel symptoms, sleep disturbance is commonly observed in patients with IBS, it being reported to occur in 26%-55% of IBS patients[28-30]. Although the cause and effect association is not clear, there is some evidence supporting the “bad bowels cause bad dream” hypothesis[31-36] including the finding that IBS patients have more frequent rapid eye movement (REM) sleep - a sleep phase that is characterized by arousal - than non-REM sleep[37,38]. IBS patients were also found to have higher rapid eye movement latency[34,39]. IBS patients with sleep dysfunction were also found to have abnormal physiological threshold of pelvic muscles. IBS patients had a significantly lower threshold volume for urge and anal sphincter pressure for maximal squeeze as compared with those without sleep dysfunction.
It has been suggested that melatonin has a sleep promoting effects by cueing circadian rhythms and thus indirectly promoting sleep. In addition, melatonin was also suggested to have a role in direct promotion of sleep. Currently, there is a general agreement that melatonin is probably not a direct soporific or hypnotic compound. Rather, the most commonly proposed mechanism for melatonin to induce sleepiness relates to its effects on the circadian clock, i.e., it “opens the sleep gate” and also it slightly reduces body temperature which promotes sleep. Clinical trials in healthy volunteers have shown that exogenous melatonin accelerates sleepiness probably via thermoregulatory mechanisms. Melatonin has these effects over a wide range of doses, ranging from physiological (250 μg) to pharmacological (1-10 mg) levels. Besides the above effects of melatonin on sleep in healthy subject or animals, many clinical trials and reviews have shown that melatonin may exert sleep promoting effect in a number of circadian rhythm sleep disorders[20,47-49].
Brain-gut interaction: mood enhancer
Patients with IBS often complain of a wide variety of symptoms apart from GI symptoms, which may not necessarily originate from the GIT but from central abnormal psychological conditions such as stress, anxiety and depression. Psychological distress and major life events are frequently present in IBS. The most common comorbid psychiatric disorders seen in IBS patients include anxiety disorders (panic and generalized anxiety disorder), depression, somatoform disorders and phobic disorders[50-52]. Compared with healthy controls, patients with IBS are observed to have higher scores for anxiety, depression, hostile feelings, sadness and interpersonal sensitivity[53-55]. In United States, Whitehead et al reported a prevalence of 30.5% for depression and 15.5% for anxiety state in IBS patients. IBS symptoms are often exacerbated by psychological stress. In Hong Kong, Generalized Anxiety Disorder was five times more common among IBS patients than non-IBS control.
Melatonin is documented to have a possible role in regulation of mood disorders, such as anxiety and depression, both of which are often caused by certain acute or chronic stress events[52,58]. Many studies reported decreases in nocturnal melatonin concentrations in depressed patients, compared with controls[19,59]. Antidepressant therapy has been reported to restore the circadian melatonin rhythm in depressive patients. It was observed that most melatonin treated women reported a general improvement in mood and a significant mitigation of depression. Reduction of nocturnal melatonin peak has been observed in depressed patients in most studies and an increase in nocturnal melatonin levels has been found in patients during treatment with desipramine[52,62].
Clinical studies in IBS patients with melatonin had mixed result when it comes to depression and anxiety. Two studies in Singapore using 3 mg of melatonin showed that there was no difference in depression and anxiety score in subjects taking melatonin compared to placebo[23,63]. Another study in India showed improvement of psychological well-being and mood in the treatment group taking 3 mg of melatonin for 2 wk, however, the details of psychological parameters were not provided.
Antinociceptive action of melatonin
The clinical finding that patients suffering less from pain during the night when melatonin level is higher led to the suggestion that melatonin has a possible analgesic effect. This suspicion was supported by the finding that pinealectomy abolished such dark phase analgesia and that it could be restored using melatonin replacement. However, the mechanism of the analgesic effects of melatonin is still not clear at present. It may include complex interactions among melatonin, opioidergic system and melatonin receptors. Met-enkephalin and beta-endorphin are two endogenous opioids involved in the regulation of pain sensitivity in hypothalamus. The levels and circadian rhythmicity of these two opioids changed in rats that received pinealectomy[66,67]. This may imply that the change in the brain concentration of these endogenous opioids could be a mechanism for the mediation of the melatonin induced modulation of pain sensitivity. However, a recent study found that melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by binding to its own receptors and increasing the release of beta-endorphin. Another study also showed that of the three other subtypes of melatonin receptors identified, i.e., Mel1, Mel2 and Mel3, only Mel2 receptor is involved in the analgesic activity of melatonin. Importantly, this anti-nociceptive effect may be unrelated to and independent of the sleep-inducing effects of melatonin, as was demonstrated in the study by Song et al, where melatonin was found to increase rectal pain thresholds but had no significant effect on sleep. Human studies have shown that melatonin is a hormone with potential therapeutic use for treatment of diseases with pain. Melatonin was documented to be effective in treating many types of headache, such as chronic cluster headache and migraines[70,71].
All these evidence support the belief that melatonin is involved in the modulation of pain and has analgesic effects. However, its potential as a therapeutic agent for treatment of diseases with pain still needs to be further investigated.
Outcomes in placebo-controlled studies
Placebo-controlled studies in melatonin suffered from heterogeneity in methodology (Table 1). Most studies utilized 3 mg at bedtime as the standard dose of trial. The duration of investigation also differ from 2 wk to 6 mo. Chojnacki et al used a twice a day dosing in their study with 3 mg in the morning and 5 mg at night for 6 mo. However, there was no increased sleepiness or gastrointestinal side effects reported (Table 2). There was a variety of outcome measures from overall IBS score to quality of life. Lu et al examined the effect of melatonin on colonic transit time (CTT) and found that melatonin increased CTT in both control and IBS patients, but only the result in control subjects was significant statistically. In other hand, Chojnacki et al showed that with 6 mo treatment with melatonin, 50% of IBS-C patients showed improvement of constipation. However, all studies had consistently showed improvement in abdominal pain for IBS patients. Song et al also reported increase of rectal pain threshold after 2 wk of melatonin treatment. Finally, Saha et al showed that the overall improvement in quality of life score was 43.63% in melatonin group and 14.64% in placebo group.
Table 1 Placebo-controlled studies: treatment effect of melatonin in irritable bowel syndrome patients.
Improved visceral pain and abdominal bloating for IBS-C patients
1CTT significantly prolonged in control subjects. Only a trend of prolonging CTT in IBS patients;
2Improved overall IBS score (45% vs 16.66%, P < 0.05);
3Significant result only for IBS-C, the intensity of visceral pain and abdominal bloating had decreased in 70% of patients (P < 0.01) and constipation in 50% of patients (P < 0.05);
4melatonin taken for two weeks significantly decreased mean abdominal pain score (2.35 vs 0.70; P < 0.001) and increased mean rectal pain threshold (8.9 vs 21.2 mmHg; P < 0.001);
5The improvement in mean ± SD. IBS symptom score was signiﬁcantly greater after treatment with melatonin (3.9 ± 2.6) than with placebo therapy (1.3 ± 4.0, P = 0.037 The beneﬁcial effects of melatonin were most marked in symptoms such as abdominal plain, abdominal distension and abnormal sensation of defecation. CTT: Colonic transit time; N/A: Not available; IBS: Irritable bowel syndrome; QOL: Quality of life.
Table 2 Placebo-controlled studies: side effects of melatonin in irritable bowel syndrome patients.
It is still unclear how melatonin may be useful and its mode of action in IBS patients. Current available evidence showed that it is likely to be useful in battling the pain and increasing pain threshold in IBS patients. Different dosing as well as treatment period of melatonin should be studied. Melatonin is a relatively safe drug that possesses potential in treating IBS. Its attractiveness also stem from its relative low cost to the patients. Future studies should focus on melatonin effect on gut mobility especially in IBS-C patients as well as its true central nervous system effect in view of high placebo rate often observed in IBS patients.
P- Reviewers: Giamarellos-Bourboulis EJ, Sinagra E S- Editor: Qi Y L- Editor: A E- Editor: Wu HL
Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects.Aliment Pharmacol Ther. 2003;17:643-650.
Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ. Epidemiology of colonic symptoms and the irritable bowel syndrome.Gastroenterology. 1991;101:927-934.
Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome.Am J Gastroenterol. 2009;104 Suppl 1:S1-35.
Ho KY, Kang JY, Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms.Am J Gastroenterol. 1998;93:1816-1822.
Gwee KA, Wee S, Wong ML, Png DJ. The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an asian urban community.Am J Gastroenterol. 2004;99:924-931.
Wong RK, Drossman DA, Weinland SR, Morris CB, Leserman J, Hu Y, Kelapure R, Bangdiwala SI. Partner burden in irritable bowel syndrome.Clin Gastroenterol Hepatol. 2013;11:151-155.
Hammerle CW, Surawicz CM. Updates on treatment of irritable bowel syndrome.World J Gastroenterol. 2008;14:2639-2649.
Srinivasan V, Pandi-Perumal SR, Trahkt I, Spence DW, Poeggeler B, Hardeland R, Cardinali DP. Melatonin and melatonergic drugs on sleep: possible mechanisms of action.Int J Neurosci. 2009;119:821-846.
Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.Curr Neuropharmacol. 2010;8:287-304.
Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions.Endocr Rev. 1991;12:151-180.
Bubenik GA, Brown GM, Grota LJ. Immunohistological localization of melatonin in the rat digestive system.Experientia. 1977;33:662-663.
Rice J, Mayor J, Tucker HA, Bielski RJ. Effect of light therapy on salivary melatonin in seasonal affective disorder.Psychiatry Res. 1995;56:221-228.
Bubenik GA, Pang SF, Hacker RR, Smith PS. Melatonin concentrations in serum and tissues of porcine gastrointestinal tract and their relationship to the intake and passage of food.J Pineal Res. 1996;21:251-256.
Drago F, Macauda S, Salehi S. Small doses of melatonin increase intestinal motility in rats.Dig Dis Sci. 2002;47:1969-1974.
Storr M, Koppitz P, Sibaev A, Saur D, Kurjak M, Franck H, Schusdziarra V, Allescher HD. Melatonin reduces non-adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro.J Pineal Res. 2002;33:101-108.
Raghavendra V, Singh V, Kulkarni SK, Agrewala JN. Melatonin enhances Th2 cell mediated immune responses: lack of sensitivity to reversal by naltrexone or benzodiazepine receptor antagonists.Mol Cell Biochem. 2001;221:57-62.
Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system.Endocrine. 2005;27:189-200.
Cuzzocrea S, Costantino G, Mazzon E, Caputi AP. Regulation of prostaglandin production in carrageenan-induced pleurisy by melatonin.J Pineal Res. 1999;27:9-14.
Crespo E, Macías M, Pozo D, Escames G, Martín M, Vives F, Guerrero JM, Acuña-Castroviejo D. Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats.FASEB J. 1999;13:1537-1546.
Deng WG, Tang ST, Tseng HP, Wu KK. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding.Blood. 2006;108:518-524.
Roberts-Thomson IC, Knight RE, Kennaway DJ, Pannall PR. Circadian rhythms in patients with abdominal pain syndromes.Aust N Z J Med. 1988;18:569-574.
Brown GM. Melatonin in psychiatric and sleep disorders.CNS Drug. 1995;3:209-226.
Bubenik GA, Blask DE, Brown GM, Maestroni GJ, Pang SF, Reiter RJ, Viswanathan M, Zisapel N. Prospects of the clinical utilization of melatonin.Biol Signals Recept. 1998;7:195-219.
Nordlund JJ, Lerner AB. The effects of oral melatonin on skin color and on the release of pituitary hormones.J Clin Endocrinol Metab. 1977;45:768-774.
Papavasiliou PS, Cotzias GC, Düby SE, Steck AJ, Bell M, Lawrence WH. Melatonin and parkinsonism.JAMA. 1972;221:88-89.
Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study.Aliment Pharmacol Ther. 2005;22:927-934.
Saha L, Malhotra S, Rana S, Bhasin D, Pandhi P. A preliminary study of melatonin in irritable bowel syndrome.J Clin Gastroenterol. 2007;41:29-32.
Corney RH, Stanton R. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome.J Psychosom Res. 1990;34:483-491.
Nyhlin H, Ford MJ, Eastwood J, Smith JH, Nicol EF, Elton RA, Eastwood MA. Non-alimentary aspects of the irritable bowel syndrome.J Psychosom Res. 1993;37:155-162.
Orr WC. Sleep and functional bowel disorders: can bad bowels cause bad dreams?Am J Gastroenterol. 2000;95:1118-1121.
Goldsmith G, Levin JS. Effect of sleep quality on symptoms of irritable bowel syndrome.Dig Dis Sci. 1993;38:1809-1814.
Jarrett M, Heitkemper M, Cain KC, Burr RL, Hertig V. Sleep disturbance influences gastrointestinal symptoms in women with irritable bowel syndrome.Dig Dis Sci. 2000;45:952-959.
Heitkemper M, Jarrett M, Burr R, Cain KC, Landis C, Lentz M, Poppe A. Subjective and objective sleep indices in women with irritable bowel syndrome.Neurogastroenterol Motil. 2005;17:523-530.
Cremonini F, Camilleri M, Zinsmeister AR, Herrick LM, Beebe T, Talley NJ. Sleep disturbances are linked to both upper and lower gastrointestinal symptoms in the general population.Neurogastroenterol Motil. 2009;21:128-135.
Miwa H. Life style in persons with functional gastrointestinal disorders--large-scale internet survey of lifestyle in Japan.Neurogastroenterol Motil. 2012;24:464-471, e217.
Kumar D, Thompson PD, Wingate DL, Vesselinova-Jenkins CK, Libby G. Abnormal REM sleep in the irritable bowel syndrome.Gastroenterology. 1992;103:12-17.
Orr WC, Crowell MD, Lin B, Harnish MJ, Chen JD. Sleep and gastric function in irritable bowel syndrome: derailing the brain-gut axis.Gut. 1997;41:390-393.
Bellini M, Gemignani A, Gambaccini D, Toti S, Menicucci D, Stasi C, Costa F, Mumolo MG, Ricchiuti A, Bedini R. Evaluation of latent links between irritable bowel syndrome and sleep quality.World J Gastroenterol. 2011;17:5089-5096.
Chen CL, Liu TT, Yi CH, Orr WC. Evidence for altered anorectal function in irritable bowel syndrome patients with sleep disturbance.Digestion. 2011;84:247-251.
Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve.Chronobiol Int. 1992;9:380-392.
Dollins AB, Lynch HJ, Wurtman RJ, Deng MH, Kischka KU, Gleason RE, Lieberman HR. Effect of pharmacological daytime doses of melatonin on human mood and performance.Psychopharmacology (Berl). 1993;112:490-496.
Kennaway DJ, Wright H. Melatonin and circadian rhythms.Curr Top Med Chem. 2002;2:199-209.
Gilbert SS, van den Heuvel CJ, Dawson D. Daytime melatonin and temazepam in young adult humans: equivalent effects on sleep latency and body temperatures.J Physiol. 1999;514:905-914.
Cajochen C, Kräuchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep.J Neuroendocrinol. 2003;15:432-437.
Claustrat B, Brun J, David M, Sassolas G, Chazot G. Melatonin and jet lag: confirmatory result using a simplified protocol.Biol Psychiatry. 1992;32:705-711.
Kunz D, Mahlberg R, Müller C, Tilmann A, Bes F. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials.J Clin Endocrinol Metab. 2004;89:128-134.
Hughes RJ, Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans.Sleep. 1997;20:124-131.
Surdea-Blaga T, Băban A, Dumitrascu DL. Psychosocial determinants of irritable bowel syndrome.World J Gastroenterol. 2012;18:616-626.
Sandyk R, Pardeshi R. Mood-dependent fluctuations in the severity of tardive dyskinesia and psoriasis vulgaris in a patient with schizoaffective disorder: possible role of melatonin.Int J Neurosci. 1990;50:215-221.
Drossman DA, Chang L. Psychosocial factors in the care of patients with GI disorders.Textbook of gastroenterology. Philadelphia: Lippincott-Raven 2003; 636-654.
Whitehead WE, Engel BT, Schuster MM. Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients.Dig Dis Sci. 1980;25:404-413.
Gomborone J, Dewsnap P, Libby G, Farthing M. Abnormal illness attitudes in patients with irritable bowel syndrome.J Psychosom Res. 1995;39:227-230.
[Georgiĭ Iosifovich Burchinskiĭ (on his 70th birthday)]. Klin Med (Mosk). 1978;56:3-5.
Whitehead WE, Palsson OS, Levy RR, Feld AD, Turner M, Von Korff M. Comorbidity in irritable bowel syndrome.Am J Gastroenterol. 2007;102:2767-2776.
Lee S, Wu J, Ma YL, Tsang A, Guo WJ, Sung J. Irritable bowel syndrome is strongly associated with generalized anxiety disorder: a community study.Aliment Pharmacol Ther. 2009;30:643-651.
Pierrefiche G, Zerbib R, Laborit H. Anxiolytic activity of melatonin in mice: involvement of benzodiazepine receptors.Res Commun Chem Pathol Pharmacol. 1993;82:131-142.
Kopp C, Vogel E, Rettori MC, Delagrange P, Misslin R. The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice.Behav Pharmacol. 1999;10:73-83.
Brown GM. Day-night rhythm disturbance, pineal function and human disease.Horm Res. 1992;37 Suppl 3:105-111.
Bellipanni G, Bianchi P, Pierpaoli W, Bulian D, Ilyia E. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study.Exp Gerontol. 2001;36:297-310.
Brown GM. Neuroendocrine probes as biological markers of affective disorders: new directions.Can J Psychiatry. 1989;34:819-823.
Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study.Gut. 2005;54:1402-1407.
Lakin ML, Miller CH, Stott ML, Winters WD. Involvement of the pineal gland and melatonin in murine analgesia.Life Sci. 1981;29:2543-2551.
John TM, Brown MC, Wideman L, Brown GM. Melatonin replacement nullifies the effect of light-induced functional pinealectomy on nociceptive rhythm in the rat.Physiol Behav. 1994;55:735-739.
Kumar MS, Chen CL, Sharp DC, Liu JM, Kalra PS, Kalra SP. Diurnal fluctuations in methionine-enkephalin levels in the hypothalamus and preoptic area of the male rat: effects of pinealectomy.Neuroendocrinology. 1982;35:28-31.
Ebadi M, Govitrapong P, Phansuwan-Pujito P, Nelson F, Reiter RJ. Pineal opioid receptors and analgesic action of melatonin.J Pineal Res. 1998;24:193-200.
Shavali S, Ho B, Govitrapong P, Sawlom S, Ajjimaporn A, Klongpanichapak S, Ebadi M. Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of beta-endorphin an endogenous opioid.Brain Res Bull. 2005;64:471-479.
Ray M, Mediratta PK, Mahajan P, Sharma KK. Evaluation of the role of melatonin in formalin-induced pain response in mice.Indian J Med Sci. 2004;58:122-130.
Peres MF, Rozen TD. Melatonin in the preventive treatment of chronic cluster headache.Cephalalgia. 2001;21:993-995.
Peres MF, Zukerman E, da Cunha Tanuri F, Moreira FR, Cipolla-Neto J. Melatonin, 3 mg, is effective for migraine prevention.Neurology. 2004;63:757.
Chojnacki C, Walecka-Kapica E, Lokieć K, Pawłowicz M, Winczyk K, Chojnacki J, Klupińska G. Influence of melatonin on symptoms of irritable bowel syndrome in postmenopausal women.Endokrynol Pol. 2013;64:114-120.
Lu WZ, Song GH, Gwee KA, Ho KY. The effects of melatonin on colonic transit time in normal controls and IBS patients.Dig Dis Sci. 2009;54:1087-1093.